On Feb. 21, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced it had approved $98,592,155…
On Feb. 21, 2024, the World Health Organization (WHO) reported that more than half the world’s countries will…
On Feb. 14, 2024, the National Institute of Allergy and Infectious Diseases (NIAID) reported study results that showed…
On Feb. 6, 2024, Oregon Health & Science University (OHSU) announced research that revealed as much as a…
On Feb. 5, 2024, CSL and and Arcturus Therapeutics announced the results of a follow-up analysis of a…
On Jan. 31, 2024, a U.S. Centers for Disease Control and Prevention (CDC) co-authored study published in Influenza…
On Jan. 25, 2024, an historic study out of Scotland showed the real-world impact of vaccines against the…
On Jan. 4, 2024, AstraZeneca Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, was approved in China for the…
On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…
On Dec. 21, 2023, the World Health Organization (WHO) announced that it had prequalified the R21/Matrix-M malaria vaccine…
On Dec. 19, 2023, COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020,…
On Dec. 18, 2023, the Novo Nordisk Foundation announced it was committing up to DKK 1.8 billion (USD…
On Dec. 18, 2023, COVID-19 vaccine maker BioNTech (22UAy.DE) announced that it aims to start production at its…
On Dec. 18, 2023, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
On Dec. 18, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced a study that showed…
On Dec. 14, 2023, The Coalition for Epidemic Preparedness Innovations (CEPI) and PATH today announced a renewed collaboration…
On Dec. 6, 2023, Anixa Biosciences announced updated positive results from the Phase 1 clinical trial of its…
On Dec. 5, 2023, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid XBB.1.5 Vaccine (Recombinant…
On Dec. 1, 2023, the World Health Organization (WHO) announced that the International Health Regulations National Focal Point…
On Nov. 29, 2023, Novavax’s partner, SK bioscience, announced that Novavax’s updated COVID-19 vaccine (NVX-CoV2601) had received Emergency…
On Nov. 29, 2023, the World Health Organization (WHO) announced that between 24 and 25 November 2023, the…
On Nov. 28, 2023, Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) had been granted Emergency Use Listing…
On Nov. 28, 2023, Emergent BioSolutions announced that the Biomedical Advanced Research and Development Authority (BARDA) within the…
On Nov. 28, 2023, CSL and Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor and Welfare (MHLW)…
On Nov. 27, 2023, University of Wisconsin-Madison researchers released a study that showed COVID-19 caused an alarming surge…
On Nov. 17, 2023, the Oregon Department of Agriculture reported that the United States Department of Agriculture’s National…
On Nov. 15, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced that it had approved…
On Nov. 10, 2023, the Centers for Disease Control and Prevention (CDC) estimated that from October 1, 2023,…
On Nov. 9, 2023, the U.S. Food and Drug Administration approved Valneva’s Ixchiq, the first chikungunya vaccine. Ixchiq…
On Oct. 31, 2023, Novavax announced that the European Commission had granted approval for Nuvaxovid XBB.1.5 dispersion for…